Find Clinical Trials

September 7, 2022 in Other Sites

TAPISTRY

TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL
Read More
August 31, 2022 in Other Sites

SGNTUC-019

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Read More
August 31, 2022 in Other Sites

CRESTONE

A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
Read More
July 11, 2022 in Other Sites

U19075

U19075: Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Read More
July 11, 2022 in Other Sites

S2012

S2012: Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Read More
July 11, 2022 in Other Sites

S1614

S1614: Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
Read More
July 11, 2022 in Other Sites

S1609

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Read More
July 1, 2022 in Other Sites

N0577

Phase III Intergroup Study of Temozolomide Alone vs. Radiotherapy with Concomitant and Adjuvant Temozolomide vs. Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
Read More
July 1, 2022 in Other Sites

Mirati/KRYSTAL-1

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Read More
June 30, 2022 in Other Sites

EAY131

Molecular Analysis for Therapy Choice (MATCH) – For all solid tumors or lymphoma that has progressed following at least one line of standard systemic therapy and/or for whose disease no…
Read More
June 30, 2022 in Other Sites

BVD-523-ABC

A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Read More
June 30, 2022 in Other Sites

A151804

A151804: Establishment of a national biorepository to advance studies of immune-related adverse events
Read More
June 29, 2022 in Other Sites

A021804

A021804: A prospective, multi-institutional phase II trial evaluating temozolomide vs. temozolomide and olaparib for advanced pheochromocytoma and paraganglioma, NCT04394858
Read More